el u tax intracranial
TRANSCRIPT
-
8/14/2019 El u Tax Intracranial
1/3
Aachen Resonance GmbH
Pauwelsstrasse 19, 52074 Aachen, Tel. +49-(0)241-97900905, Fax +49-(0)241-97900907, E-Mail: [email protected]
Aachen, Germany, 14.01.2009
First in man use of a Drug eluting Balloon for treatment of intracranial
Stenosis
Symptomatic intracranial stenoses have a high risk for a recurrent stroke if
treated medically. Although angioplasty and stent placement are proposed
treatment options, data shows a poor long-term outcome.
Mortality rate when untreated is more than 20% in a period of 24 months.
Prof. Juergen Reul of Beta Klinik, Bonn, Germany, used successfully and at
the first time in the world the Elutax Balloon catheter in a case of triple A.
basilaris stenosis. The contra lateral A. basilaris was already occluded.
Before treatment:
Due to the triple-lesions anatomy a stent placement was not the first option,as the tortuosity of the vessel could jeopardize the successful placement.
After treatment with Elutax:
-
8/14/2019 El u Tax Intracranial
2/3
The triple restenosis is resolved and the blood flow is restored successfully.
The Aachen Resonance Elutax Drug eluting Balloon, a life saving device, was
used to help the patient.
Elutax is developed especially for small vessels. The balloon is coated with 2
microgram/mm2 pure Paclitaxel. As there is no stent mounted on the balloon,
the pushability and the positioning of the device is facilitated compared to a
balloon with a stent.
The stenosis is caused by neointimal cell hyperplasia. Local administration oflipophilic paclitaxel compounds inhibits the proliferation of such cells for a long
period.
About Aachen Resonance:
-
8/14/2019 El u Tax Intracranial
3/3
Aachen Resonance is a leading European manufacturer of medical
technology with a worldwide market presence. The company offers a
complete line of products for treatment and advanced therapy support in
vascular intervention, working in close cooperation with the University of
Technology in Aachen.
Its main focus is developing new devices with improved biocompatibility
The field of vascular intervention consists of balloon catheters, stents, drug
eluting stents and drug eluting balloons for coronary and peripheral
applications.
The company invests heavily in research and development, and is pursuing
important, future-oriented approaches to cardiovascular therapy. Currently,
Aachen Resonance maintains three headquarters in Europe for research,
development and manufacturing.
Aachen Resonance is market leader in Europe for Drug eluting balloons.
Contact address:
Dr. Alexander Ruebben, CEO
Aachen Resonance GmbH
Pauwelsstrasse 19D-52074 Aachen
Germany
Tel. 0049 241 97900905
Fax. 0049 241 97900907
www.aachen-resonance.com
Email: [email protected]
http://service.gmx.net/de/cgi/derefer?TYPE=3&DEST=http%3A%2F%2Fwww.aachen-resonance.comhttp://service.gmx.net/de/cgi/g.fcgi/mail/new?CUSTOMERNO=8419587&t=de1059525397.1231962370.55e33332&[email protected]://service.gmx.net/de/cgi/g.fcgi/mail/new?CUSTOMERNO=8419587&t=de1059525397.1231962370.55e33332&[email protected]://service.gmx.net/de/cgi/derefer?TYPE=3&DEST=http%3A%2F%2Fwww.aachen-resonance.com